12 Posters and Presentations Featuring MolecuLight to be Presented at the SAWC Fall 2023 Conference

The clinical presentation and posters featuring the MolecuLight i:X and DX from SAWC Fall 2023 are as follows:CLINICAL PRESENTATIONS The clinical presentation and posters featuring the MolecuLight i: XandDXfrom SAWC Fall 2023 are as follows: CLINICAL PRESENTATIONS b) CLINICALPOSTERS In addition to the clinical posters and presentations atSAWC Fall 2023, the MolecuLight i: X®andDX ™ imaging devices will be available for demonstration in the MolecuLight booth...

The clinical presentation and posters featuring the MolecuLight i:X and DX from SAWC Fall 2023 are as follows:

CLINICAL PRESENTATIONS

b) CLINICALPOSTERS

In addition to the clinical posters and presentations at SAWC Fall 2023, the MolecuLight i:X® and DX™ imaging devices will be available for demonstration in the MolecuLight booth #430 in the Octavius Ballroom (Level 3) at Caesars Palace, Las Vegas, NV.

The MolecuLight i:X® and DX™ are the only imaging devices for the real-time detection of elevated bacterial burden in wounds that are FDA cleared and CE and Health Canada Approved. With unmatched clinical evidence including over 80 peer-reviewed publications and 2,600 patients, they are used by leading wound care facilities globally.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercial devices, which include the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform "fluorescence imaging for bacterial presence, location, and load" and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

Rob Sandler, Chief Marketing Officer, MolecuLight Inc., T. +1.647.362.4684, rsandler@moleculight.com, www.moleculight.com 

Photo - https://mma.prnewswire.com/media/2264598/MolecuLight_12_Posters_and_Presentations_Featuring_MolecuLight_t.jpg

Photo - https://mma.prnewswire.com/media/2264599/MolecuLight_12_Posters_and_Presentations_Featuring_MolecuLight_t.jpg

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/12-posters-and-presentations-featuring-moleculight-to-be-presented-at-the-sawc-fall-2023-conference-301975462.html